Discover
Survey Report
What’s Next for Cell and Gene Therapy: CGT Executive Perspectives
Obstacles and opportunities for the industry, from the point of view of those leading it
Survey Report
Cell and Gene Therapy Trends Survey: How CGT Leaders See the Future
Cell and gene therapy has entered a new phase of maturity, and to better understand how industry leaders are navigating this shift, Precision for Medicine and Precision AQ partnered with the Alliance for Regenerative Medicine (ARM) to survey nearly 50 cell and gene therapy executives across the industry.
The findings reveal what barriers remain, where organizations are investing, and the strategies shaping the next era of CGT development and commercialization.
The Consensus: Gene and Cell Therapy is Entering its Execution Era
Across the board, CGT executives agreed that the question is no longer “will the therapy work?” but rather “will it sell?”, with discussion centered upon:
- Building confidence in the predictable application of regulatory policy
- Barriers to adoption and what organizations are doing to expand patient access
- Addressing delivery constraints alongside increasing competitive pressures
Download the report to see the full survey findings and how they provide a blueprint for every cell and gene therapy developer’s next chapter.
Download the Survey Report
Bonus Content: Hear Expert Perspectives
Precision's Dr. Harpreet Singh joined Dr. Seth Ettenberg, President and CEO of BlueRock Therapeutics, for a Spotlight Presentation on these survey findings during the 2026 Cell & Gene Meeting on the Mesa.
You’ll find videos embedded throughout the report with highlights from their discussion on the implications of key results.
Curated Insights
Stay ahead with the latest insights in cell and gene therapy innovation from our experts.
Case Study: Managing Complexity in an Autologous Cell Therapy Trial
Early Phase Research - Gene Therapies
Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy
|
Discover